Rowlandmiller & PARTNERS.ADV Has $5.84 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Rowlandmiller & PARTNERS.ADV lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 1.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,115 shares of the medical research company’s stock after selling 290 shares during the quarter. Amgen comprises about 1.2% of Rowlandmiller & PARTNERS.ADV’s investment portfolio, making the stock its 24th largest holding. Rowlandmiller & PARTNERS.ADV’s holdings in Amgen were worth $5,837,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new stake in shares of Amgen in the second quarter worth about $26,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen in the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the second quarter valued at approximately $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter valued at approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday. Royal Bank of Canada restated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. Oppenheimer restated an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Finally, Barclays raised their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $332.55.

Amgen Stock Up 0.3 %

Shares of AMGN opened at $315.69 on Friday. The company has a market capitalization of $169.35 billion, a PE ratio of 45.10, a PEG ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85. The stock’s 50-day moving average price is $325.77 and its two-hundred day moving average price is $313.12. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.00 earnings per share. On average, analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.